Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$26.94
-$0.03(-0.09%)
At close: 4:00 PM EST
$26.94
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)873.27K
Market Cap
$1.57B
Enterprise Value$1.52B
Total Cash (Recent Filing)$952.86M
Total Debt (Recent Filing)$44.52M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Feb 12, 2026EPS Estimate
-1.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,313,812
10 Day Avg. Volume892,301
30 Day Avg. Volume873,269
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue34.00
Enterprise Value/Gross Profit40.28
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$36.14Price Target Upside34.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Opportunity And Administration AdvantageOral administration and broad labeling position mitapivat to capture a larger share of the thalassemia market versus injectable competitors, enhancing commercial upside.
Physician Adoption And Commercial ReadinessHigh reported physician intent to prescribe combined with the company's established Pyrukynd commercial infrastructure supports scalable launch execution and early uptake.
Regulatory ApprovalFDA approval of mitapivat (Aqvesme) with a broad label covering both transfusion‑dependent and non‑transfusion‑dependent alpha‑ and beta‑thalassemia creates a large eligible patient population for treatment.
Bears Say
Regulatory Uncertainty For Sickle Cell ExpansionAn uncertain and potentially more complex regulatory path in sickle cell disease represents an overhang that could limit future label expansion and upside.
REMS Monitoring BurdenREMS-mandated liver monitoring and prescriber certification introduce additional management requirements that could complicate patient access and slow uptake.
Safety Overhang And Black Box WarningA black box warning for hepatocellular injury and prior adverse reactions create a safety overhang that may increase payer scrutiny and constrain prescribing momentum.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.57B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Feb 12, 2026 which is today.
How were Agios Pharma’s earnings last quarter?
Currently, no data Available
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.95.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,313,812 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.14 (34.15% Upside)
$36.14 (34.15% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 183.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 13.6%
Last 30 Days ▼ 13.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.48%
12-Months-Change
Fundamentals
Return on Equity
-27.57%
Trailing 12-Months
Asset Growth
-22.66%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, global regulatory progress, and significant pipeline advancements. However, there are challenges with increased expenses and potential regulatory hurdles related to the REMS program.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$36.14
▲(34.15% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---